Access the full text.
Sign up today, get DeepDyve free for 14 days.
J. Langowski, Xueqing Zhang, Lingling Wu, J. Mattson, Taiying Chen, Kathy Smith, B. Basham, T. Mcclanahan, R. Kastelein, M. Oft (2006)
IL-23 promotes tumour incidence and growthNature, 442
J. Sieper, B. Porter-Brown, L. Thompson, O. Harari, M. Dougados (2013)
Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trialsAnnals of the Rheumatic Diseases, 73
F. Ortiz-Sanjuan, R. Blanco, L. Riancho-Zarrabeitia, S. Castañeda, A. Olivé, A. Riveros, M. Velloso-Feijoó, J. Narváez, I. Jiménez-Moleón, O. Maíz-Alonso, C. Ordóñez, J. Bernal, María Hernandez, W. Sifuentes-Giraldo, C. Gómez-Arango, E. Galíndez-Agirregoikoa, J. Blanco-madrigal, V. Ortiz-Santamaria, J. Blanco-Barnusell, J. Dios, M. Moreno, J. Fiter, M. Riscos, P. Carreira, María Rodriguez-Valls, M. Gonzalez-vela, V. Calvo-Río, J. Loricera, N. Palmou-Fontana, T. Pina, J. Llorca, M. González-Gay (2015)
Efficacy of Anakinra in Refractory Adult-Onset Still's DiseaseMedicine, 94
N. Tugnet, A. Youssef, A. Whallett (2012)
Wells' syndrome (eosinophilic cellulitis) secondary to infliximab.Rheumatology, 51 1
Sophia Kim, G. Marigowda, Eyal Oren, E. Israel, M. Wechsler (2010)
Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome.The Journal of allergy and clinical immunology, 125 6
D. Wendling, Hélène Letho-Gyselinck, X. Guillot, C. Prati (2012)
Psoriasis Onset with Tocilizumab Treatment for Rheumatoid ArthritisThe Journal of Rheumatology, 39
O. Boyman, D. Comte, F. Spertini (2014)
Adverse reactions to biologic agents and their medical managementNature Reviews Rheumatology, 10
H. Hoffman, M. Throne, N. Amar, R. Cartwright, A. Kivitz, Y. Soo, S. Weinstein (2012)
Long-term efficacy and safety profile of rilonacept in the treatment of cryopryin-associated periodic syndromes: results of a 72-week open-label extension study.Clinical therapeutics, 34 10
P. Gevaert, N. Bruaene, T. Cattaert, K. Steen, T. Zele, F. Acke, N. Ruyck, Katrien Blomme, A. Sousa, R. Marshall, C. Bachert (2011)
Rhinitis , sinusitis , and upper airway disease Mepolizumab , a humanized anti – IL-5 mAb , as a treatment option for severe nasal polyposis
J. Kuemmerle-Deschner, F. Hofer, T. Endres, B. Kortus-Goetze, N. Blank, E. Weissbarth-Riedel, C. Schuetz, T. Kallinich, K. Krause, C. Rietschel, G. Horneff, S. Benseler (2016)
Real-life effectiveness of canakinumab in cryopyrin-associated periodic syndrome.Rheumatology, 55 4
C. Kauffman, N. Aria, E. Toichi, T. McCormick, K. Cooper, A. Gottlieb, D. Everitt, B. Frederick, Yaowei Zhu, M. Graham, C. Pendley, M. Mascelli (2004)
A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis.The Journal of investigative dermatology, 123 6
E. Fréling, C. Baumann, J. Cuny, M. Bigard, J. Schmutz, A. Barbaud, L. Peyrin-Biroulet (2015)
Cumulative Incidence of, Risk Factors for, and Outcome of Dermatological Complications of Anti-TNF Therapy in Inflammatory Bowel Disease: A 14-Year ExperienceThe American Journal of Gastroenterology, 110
M. Wechsler, P. Akuthota, D. Jayne, P. Khoury, A. Klion, C. Langford, P. Merkel, F. Moosig, U. Specks, M. Cid, R. Luqmani, Judith Brown, S. Mallett, R. Philipson, S. Yancey, J. Steinfeld, P. Weller, G. Gleich (2017)
Mepolizumab or Placebo for Eosinophilic Granulomatosis with PolyangiitisThe New England Journal of Medicine, 376
J. Jung, E. Levin, Robert Jarrett, Dongsi Lu, C. Mann (2011)
Lymphomatoid drug reaction to ustekinumab.Archives of dermatology, 147 8
J. Becker, J. Mundi, Tracey Newlove, J. Mones, J. Shupack (2012)
Development of linear IgA bullous dermatosis in a patient with psoriasis taking ustekinumab.Journal of the American Academy of Dermatology, 67 4
N. Palmou-Fontana, Juan Gaviño, D. McGonagle, E. García-Martínez, L. Martín (2014)
Tocilizumab-Induced Psoriasiform Rash in Rheumatoid ArthritisDermatology, 228
C. Hua, L. Boussemart, C. Mateus, É. Routier, C. Boutros, H. Cazenave, R. Viollet, Marina Thomas, Séverine Roy, N. Benannoune, G. Tomasic, J. Soria, S. Champiat, M. Texier, E. Lanoy, C. Robert (2016)
Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab.JAMA dermatology, 152 1
A. Afzali, C. Wheat, J. Hu, J. Olerud, S. Lee (2014)
The association of psoriasiform rash with anti-tumor necrosis factor (anti-TNF) therapy in inflammatory bowel disease: a single academic center case series.Journal of Crohn's & colitis, 8 6
P. Gevaert, D. Lang‐Loidolt, A. Lackner, H. Stammberger, H. Staudinger, T. Zele, G. Holtappels, J. Tavernier, P. Cauwenberge, C. Bachert (2006)
Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps.The Journal of allergy and clinical immunology, 118 5
J. Wollenhaupt, J. Silverfield, E. Lee, J. Curtis, S. Wood, K. Soma, C. Nduaka, B. Benda, D. Gruben, Hiroyuki Nakamura, Y. Komuro, S. Zwillich, Lisy Wang, R. Riese (2014)
Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, for the Treatment of Rheumatoid Arthritis in Open-label, Longterm Extension StudiesThe Journal of Rheumatology, 41
M. Khellaf, A. Charles-Nelson, O. Fain, L. Terriou, J. Viallard, S. Cheze, J. Graveleau, B. Slama, S. Audia, M. Ebbo, G. Guenno, M. Cliquennois, G. Salles, C. Bonmati, F. Teillet, L. Galicier, A. Hot, O. Lambotte, F. Lefrère, S. Sacko, Dieudonné Kengue, P. Bierling, F. Roudot-thoraval, M. Michel, B. Godeau (2014)
Safety and efficacy of rituximab in adult immune thrombocytopenia: results from a prospective registry including 248 patients.Blood, 124 22
A. Hahn, D. Gill, N. Agarwal, B. Maughan (2017)
PD-1 checkpoint inhibition: Toxicities and management.Urologic oncology, 35 12
Brooke Rothstein, A. Gottlieb (2016)
Secukinumab for treating plaque psoriasisExpert Opinion on Biological Therapy, 16
D. Thaçi, A. Blauvelt, K. Reich, T. Tsai, F. Vanaclocha, K. Kingo, M. Ziv, A. Pinter, S. Hugot, R. You, M. Milutinovic (2015)
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial.Journal of the American Academy of Dermatology, 73 3
J. Hodge, T. Kawabata, S. Krishnaswami, J. Clark, J. Telliez, M. Dowty, S. Menon, M. Lamba, S. Zwillich (2016)
The mechanism of action of tofacitinib - an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis.Clinical and experimental rheumatology, 34 2
M. Brunda, L. Luistro, R. Warrier, R. Wright, B. Hubbard, Molly Murphy, S. Wolf, M. Gately (1993)
Antitumor and antimetastatic activity of interleukin 12 against murine tumorsThe Journal of Experimental Medicine, 178
K. Bryant, Matthew DeNunzio, M. Ford (2016)
Linear IgA dermatosis after infliximab infusion for ulcerative colitisJAAD Case Reports, 2
Lucy Liu, B. Craiglow, B. King (2018)
Tofacitinib 2% ointment, a topical Janus kinase inhibitor, for the treatment of alopecia areata: A pilot study of 10 patientsJournal of the American Academy of Dermatology, 78
C. Bachert, C. Bachert, L. Mannent, R. Naclerio, J. Mullol, B. Ferguson, P. Gevaert, P. Hellings, L. Jiao, Ling Wang, R. Evans, G. Pirozzi, N. Graham, B. Swanson, J. Hamilton, A. Radin, N. Gandhi, N. Stahl, G. Yancopoulos, E. Sutherland (2016)
Effect of Subcutaneous Dupilumab on Nasal Polyp Burden in Patients With Chronic Sinusitis and Nasal Polyposis: A Randomized Clinical Trial.JAMA, 315 5
A. Russell, G. Wallenstein, Tracy Li, Marie Martin, R. Maclean, B. Blaisdell, K. Gajria, J. Cole, J. Becker, P. Emery (2006)
Abatacept improves both the physical and mental health of patients with rheumatoid arthritis who have inadequate response to methotrexate treatmentAnnals of the Rheumatic Diseases, 66
M. Lebwohl, B. Strober, A. Menter, K. Gordon, J. Węgłowska, L. Puig, K. Papp, L. Spelman, D. Toth, F. Kerdel, A. Armstrong, G. Stingl, A. Kimball, H. Bachelez, Jashin Wu, J. Crowley, R. Langley, T. Blicharski, C. Paul, J. Lacour, S. Tyring, L. Kircik, S. Chimenti, K. Duffin, J. Bagel, J. Koo, G. Aras, Joanne Li, Wenjie Song, Cassandra Milmont, Yifei Shi, N. Erondu, P. Klekotka, B. Kotzin, A. Nirula (2015)
Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis.The New England journal of medicine, 373 14
M. Fernández-Megía, B. Casanova, M. Magraner, I. Font-Noguera, J. Poveda-Andrés (2011)
Assessment of the effectiveness and safety of natalizumab for treating relapsing-remitting multiple sclerosis.Farmacia Hospitalaria, 35
P. Mease, A. Gottlieb, D. Heijde, O. FitzGerald, A. Johnsen, M. Nys, Subhashish Banerjee, D. Gladman (2017)
Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritisAnnals of the Rheumatic Diseases, 76
G. Krueger, R. Langley, C. Leonardi, N. Yeilding, C. Guzzo, Yuhua Wang, L. Dooley, M. Lebwohl (2007)
A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis.The New England journal of medicine, 356 6
P. Karmacharya, D. Poudel, R. Pathak, A. Donato, Sushil Ghimire, S. Giri, M. Aryal, C. Bingham (2015)
Rituximab-induced serum sickness: A systematic review.Seminars in arthritis and rheumatism, 45 3
O. Sokumbi, D. Wetter, A. Makol, K. Warrington (2012)
Vasculitis associated with tumor necrosis factor-α inhibitors.Mayo Clinic proceedings, 87 8
A. Golmia, B. Grinblat, E. Finger, C. Klieman, F. Assir, M. Scheinberg (2007)
The development of erythema elevatum diutinum in a patient with juvenile idiopathic arthritis under treatment with abataceptClinical Rheumatology, 27
C. Friedman, T. Proverbs-Singh, M. Postow (2016)
Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors: A Review.JAMA oncology, 2 10
Stephanie Liu, N. Velez, C. Lam, A. Femia, S. Granter, H. Townsend, R. Vleugels (2013)
Dermatomyositis induced by anti-tumor necrosis factor in a patient with juvenile idiopathic arthritis.JAMA dermatology, 149 10
F. Rhee, C. Casper, P. Voorhees, L. Fayad, H. Velde, J. Vermeulen, X. Qin, M. Qi, B. Tromp, R. Kurzrock (2015)
A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman diseaseOncotarget, 6
D. Lovell, N. Ruperto, R. Mouy, E. Paz, N. Rubio-Pérez, C. Silva, C. Abud-Mendoza, R. Burgos-Vargas, V. Gerloni, J. Melo-Gomes, C. Saad-Magalhães, J. Chávez-Corrales, C. Huemer, A. Kivitz, F. Blanco, I. Foeldvari, M. Hofer, H. Huppertz, C. Deslandre, K. Minden, M. Punaro, A. Block, E. Giannini, A. Martini (2015)
Long‐Term Safety, Efficacy, and Quality of Life in Patients With Juvenile Idiopathic Arthritis Treated With Intravenous Abatacept for Up to Seven YearsArthritis & Rheumatology (Hoboken, N.j.), 67
J. Larkin, V. Chiarion-Sileni, R. Gonzalez, J. Grob, C. Cowey, C. Lao, D. Schadendorf, R. Dummer, M. Smylie, P. Rutkowski, P. Ferrucci, A. Hill, J. Wagstaff, M. Carlino, J. Haanen, M. Maio, I. Márquez-Rodas, G. McArthur, P. Ascierto, G. Long, M. Callahan, M. Postow, M. Postow, K. Grossmann, M. Sznol, B. Dréno, L. Bastholt, A. Yang, L. Rollin, C. Horak, F. Hodi, J. Wolchok, J. Wolchok (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.The New England journal of medicine, 373 1
V. Tzanetakou, T. Kanni, S. Giatrakou, A. Katoulis, E. Papadavid, M. Netea, C. Dinarello, J. Meer, D. Rigopoulos, E. Giamarellos‐Bourboulis (2016)
Safety and Efficacy of Anakinra in Severe Hidradenitis Suppurativa: A Randomized Clinical Trial.JAMA dermatology, 152 1
R. Langley, M. Lebwohl, G. Krueger, Philippe Szapary, Y. Wasfi, D. Chan, M. Hsu, Y. You, Y. Poulin, N. Korman, J. Prinz, K. Reich (2015)
Long‐term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate‐to‐severe psoriasis: results from the PHOENIX 2 study through 5 years of follow‐upBritish Journal of Dermatology, 172
M. Long, Christopher Martin, Clare Pipkin, H. Herfarth, R. Sandler, M. Kappelman (2012)
Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease.Gastroenterology, 143 2
A. Maeda, S. Schneider, M. Kojima, S. Beissert, T. Schwarz, A. Schwarz (2006)
Enhanced photocarcinogenesis in interleukin-12-deficient mice.Cancer research, 66 6
Huyen Tran, T. Brighton, A. Grigg, S. Mcrae, Joanna Dixon, D. Thurley, M. Gandhi, M. Truman, P. Marlton, J. Catalano (2014)
A multi‐centre, single‐arm, open‐label study evaluating the safety and efficacy of fixed dose rituximab in patients with refractory, relapsed or chronic idiopathic thrombocytopenic purpura (R‐ITP1000 study)British Journal of Haematology, 167
C. Leonardi, A. Kimball, K. Papp, N. Yeilding, C. Guzzo, Yuhua Wang, Shu Li, L. Dooley, K. Gordon (2008)
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)The Lancet, 371
S. Tiwari, B. Wood, T. Skender-Kalnenas, N. Cook (2014)
A case of abatacept associated neutrophilic dermatosis and a review of the literatureAustralasian Journal of Dermatology, 55
S. Saw, H. Lee, Q. Ng (2017)
Pembrolizumab-induced Stevens-Johnson syndrome in non-melanoma patients.European journal of cancer, 81
J. Ramírez, M. Hernández, J. Galve, J. Cañete, R. Sanmartí (2012)
Morphea associated with the use of adalimumab: a case report and review of the literatureModern Rheumatology, 22
J. Kremer, S. Cohen, B. Wilkinson, C. Connell, J. French, J. Gómez-Reino, D. Gruben, K. Kanik, S. Krishnaswami, V. Pascual-Ramos, G. Wallenstein, S. Zwillich (2012)
A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone.Arthritis and rheumatism, 64 4
A. López-Ferrer, Ana Laiz, Lluís Puig (2017)
The safety of ustekinumab for the treatment of psoriatic arthritisExpert Opinion on Drug Safety, 16
P. Jayasekera, R. Parslew, Ali Alsharqi (2014)
A case of tumour necrosis factor‐α inhibitor‐ and rituximab‐induced plantar pustular psoriasis that completely resolved with tocilizumabBritish Journal of Dermatology, 171
A. Brucato, M. Imazio, M. Gattorno, G. Lazaros, S. Maestroni, M. Carraro, M. Finetti, D. Cumetti, A. Carobbio, N. Ruperto, R. Marcolongo, M. Lorini, A. Rimini, A. Valenti, G. Erre, M. Sormani, R. Belli, F. Gaita, A. Martini (2016)
Effect of Anakinra on Recurrent Pericarditis Among Patients With Colchicine Resistance and Corticosteroid Dependence: The AIRTRIP Randomized Clinical Trial.JAMA, 316 18
J. Schmutz, P. Tréchot (2012)
Éruption paradoxale psoriasiforme induite par l’abatacept (ORENCIA®)Annales De Dermatologie Et De Venereologie, 139
C. Polman, P. O'connor, E. Havrdová, M. Hutchinson, L. Kappos, David Miller, J. Phillips, F. Lublin, G. Giovannoni, A. Wajgt, M. Toal, F. Lynn, M. Panzara, A. Sandrock (2006)
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.The New England journal of medicine, 354 9
A. Blauvelt, M. Bruin-Weller, M. Gooderham, J. Cather, J. Weisman, D. Pariser, E. Simpson, K. Papp, H. Hong, Diana Rubel, P. Foley, E. Prens, C. Griffiths, T. Etoh, P. Pinto, R. Pujol, J. Szepietowski, K. Ettler, L. Kemény, Xiaoping Zhu, B. Akinlade, T. Hultsch, V. Mastey, A. Gadkari, L. Eckert, N. Amin, N. Graham, G. Pirozzi, N. Stahl, G. Yancopoulos, B. Shumel (2017)
Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trialThe Lancet, 389
Kohei Kato, T. Satoh, A. Nishizawa, H. Yokozeki (2011)
Psoriasiform drug eruption due to abatacept.Acta dermato-venereologica, 91 3
H. Winfield, E. Lain, T. Horn, Jerri Hoskyn (2006)
Eosinophilic cellulitislike reaction to subcutaneous etanercept injection.Archives of dermatology, 142 2
Lise Boussemart, S. Jacobelli, Frédéric Batteux, C. Goulvestre, P. Grange, A. Carlotti, J. Morini, I. Gorin, J. Ziza, M. Avril, Nicolas Dupin (2010)
Autoimmune Bullous Skin Diseases Occurring under Anti-Tumor Necrosis Factor Therapy: Two Case ReportsDermatology, 221
T. Lobatón, S. Vermeire, G. Assche, P. Rutgeerts (2014)
Review article: anti‐adhesion therapies for inflammatory bowel diseaseAlimentary Pharmacology & Therapeutics, 39
Giuliana Carlos, Rachael Anforth, S. Chou, A. Clements, P. Fernández-Peñas (2015)
A case of bullous pemphigoid in a patient with metastatic melanoma treated with pembrolizumab.Melanoma research, 25 3
K. Gordon, A. Blauvelt, K. Papp, R. Langley, T. Luger, M. Ohtsuki, K. Reich, D. Amato, S. Ball, D. Braun, G. Cameron, J. Erickson, Robert Konrad, T. Muram, B. Nickoloff, O. Osuntokun, R. Secrest, F. Zhao, L. Mallbris, C. Leonardi (2016)
Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis.The New England journal of medicine, 375 4
M. Lebwohl, C. Leonardi, C. Griffiths, J. Prinz, P. Szapary, N. Yeilding, C. Guzzo, Shu Li, M. Hsu, B. Strober (2012)
Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trials.Journal of the American Academy of Dermatology, 66 5
Gaelle Serac, F. Tubach, X. Mariette, D. Salmon-Céron, P. Ravaud, F. Lioté, D. Laharie, J. Ziza, L. Marguerie, C. Bonnet, G. Falgarone, N. Nicolas, O. Lortholary, O. Chosidow (2012)
Risk of herpes zoster in patients receiving anti-TNF-α in the prospective French RATIO registry.The Journal of investigative dermatology, 132 3 Pt 1
E. Hawryluk, K. Linskey, L. Duncan, R. Nazarian (2012)
Broad range of adverse cutaneous eruptions in patients on TNF‐alpha antagonistsJournal of Cutaneous Pathology, 39
M. Hutchinson (2007)
Natalizumab: A new treatment for relapsing remitting multiple sclerosisTherapeutics and Clinical Risk Management, 3
I. McInnes, A. Kavanaugh, A. Gottlieb, L. Puig, P. Rahman, C. Ritchlin, C. Brodmerkel, Shu Li, Yuhua Wang, A. Mendelsohn, M. Doyle (2013)
Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trialThe Lancet, 382
A. Levin, I. Otani, Timothy Lax, E. Hochberg, A. Banerji (2017)
Reactions to Rituximab in an Outpatient Infusion Center: A 5-Year Review.The journal of allergy and clinical immunology. In practice, 5 1
F. Moosig, W. Gross, K. Herrmann, J. Bremer, B. Hellmich (2011)
Targeting interleukin-5 in refractory and relapsing Churg-Strauss syndrome.Annals of internal medicine, 155 5
W. Sandborn, C. Su, B. Sands, G. D'Haens, S. Vermeire, S. Schreiber, S. Danese, B. Feagan, W. Reinisch, W. Niezychowski, G. Friedman, N. Lawendy, Dahong Yu, D. Woodworth, A. Mukherjee, Haiying Zhang, P. Healey, J. Panés (2017)
Tofacitinib as Induction and Maintenance Therapy for Ulcerative ColitisThe New England Journal of Medicine, 376
M. Gattorno, L. Obici, M. Cattalini, V. Tormey, K. Abrams, N. Davis, A. Speziale, S. Bhansali, A. Martini, H. Lachmann (2016)
Canakinumab treatment for patients with active recurrent or chronic TNF receptor-associated periodic syndrome (TRAPS): an open-label, phase II studyAnnals of the Rheumatic Diseases, 76
E. Leung, K. Efraij, J. FitzGerald (2017)
The safety of mepolizumab for the treatment of asthmaExpert Opinion on Drug Safety, 16
K. Wenk, Joan Claros, A. Ehrlich (2012)
Flare of pustular psoriasis after initiating ustekinumab therapyJournal of Dermatological Treatment, 23
E. Loftus, J. Colombel, B. Feagan, S. Vermeire, W. Sandborn, B. Sands, S. Danese, G. D'Haens, A. Kaser, R. Panaccione, D. Rubin, I. Shafran, M. McAuliffe, A. Kaviya, S. Sankoh, R. Mody, B. Abhyankar, M. Smyth (2016)
Long-term Efficacy of Vedolizumab for Ulcerative ColitisJournal of Crohn's and Colitis, 11
S. Wenzel, M. Castro, J. Corren, J. Maspero, Lin Wang, Bingzhi Zhang, G. Pirozzi, R. Sutherland, R. Evans, V. Joish, L. Eckert, N. Graham, N. Stahl, G. Yancopoulos, Mariana Louis-Tisserand, A. Teper (2016)
Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trialThe Lancet, 388
A.M.G. Brunasso, W. Aberer, C. Massone (2014)
Subacute lupus erythematosus during treatment with golimumab for seronegative rheumatoid arthritisLupus, 23
S. Pintova, H. Sidhu, P. Friedlander, R. Holcombe (2013)
Sweet's syndrome in a patient with metastatic melanoma after ipilimumab therapy.Melanoma research, 23 6
C. Griffiths, K. Reich, M. Lebwohl, P. Kerkhof, C. Paul, A. Menter, G. Cameron, J. Erickson, Lu Zhang, R. Secrest, S. Ball, D. Braun, O. Osuntokun, M. Heffernan, B. Nickoloff, K. Papp (2015)
Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trialsThe Lancet, 386
B. Farahnik, Kourosh Beroukhim, M. Abrouk, Mio Nakamura, T. Zhu, Rasnik Singh, Kristina Lee, T. Bhutani, J. Koo (2016)
Brodalumab for the Treatment of Psoriasis: A Review of Phase III TrialsDermatology and Therapy, 6
G. Brown, E. Wang, A. Leon, Monica Huynh, M. Wehner, R. Matro, E. Linos, W. Liao, A. Haemel (2017)
Tumor necrosis factor‐&agr; inhibitor‐induced psoriasis: Systematic review of clinical features, histopathological findings, and management experienceJournal of the American Academy of Dermatology, 76
W. Stohl, J. Merrill, J. McKay, J. Lisse, Z. Zhong, W. Freimuth, M. Genovese, MD Freimuth (2013)
Efficacy and Safety of Belimumab in Patients with Rheumatoid Arthritis: A Phase II, Randomized, Double-blind, Placebo-controlled, Dose-ranging StudyThe Journal of Rheumatology, 40
J. Wong, A. Long (2017)
Rituximab Hypersensitivity: Evaluation, Desensitization, and Potential Mechanisms.The journal of allergy and clinical immunology. In practice, 5 6
R. Joseph, M. Cappel, Brent Goedjen, M. Gordon, Brandon Kirsch, C. Gilstrap, S. Bagaria, A. Jambusaria-Pahlajani (2014)
Lichenoid Dermatitis in Three Patients with Metastatic Melanoma Treated with Anti–PD-1 TherapyCancer Immunology Research, 3
K. Papp, C. Griffiths, K. Gordon, M. Lebwohl, Philippe Szapary, Y. Wasfi, D. Chan, M. Hsu, V. Ho, P. Ghislain, B. Strober, K. Reich (2013)
Long‐term safety of ustekinumab in patients with moderate‐to‐severe psoriasis: final results from 5 years of follow‐upBritish Journal of Dermatology, 168
D. Thaçi, E. Simpson, Lisa Beck, T. Bieber, A. Blauvelt, K. Papp, W. Soong, M. Worm, Jacek Szepietowski, H. Sofen, M. Kawashima, R. Wu, Steven Weinstein, N. Graham, G. Pirozzi, A. Teper, E Sutherland, V. Mastey, N. Stahl, G. Yancopoulos, M. Ardeleanu (2016)
Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trialThe Lancet, 387
K. Minkis, B. Garden, Shenhong Wu, M. Pulitzer, M. Lacouture (2013)
The risk of rash associated with ipilimumab in patients with cancer: a systematic review of the literature and meta-analysis.Journal of the American Academy of Dermatology, 69 3
J. Izquierdo, F. Bonilla-Abadía, C. Ochoa, A. Agualimpia, G. Tobón, C. Cañas (2012)
Acute Generalized Exanthematous Pustulosis due to Tocilizumab in a Rheumatoid Arthritis PatientCase Reports in Rheumatology, 2012
Sonia Jain, C. Thongprayoon, R. Espinosa, S. Hayes, K. Klarich, L. Cooper, K. Moder, N. Anavekar, Jae Oh, E. Matteson (2015)
Effectiveness and Safety of Anakinra for Management of Refractory Pericarditis.The American journal of cardiology, 116 8
P. Hashkes, S. Spalding, E. Giannini, Bin Huang, Anne Johnson, G. Park, K. Barron, M. Weisman, N. Pashinian, A. Reiff, J. Samuels, D. Wright, D. Kastner, D. Lovell (2012)
Rilonacept for Colchicine-Resistant or -Intolerant Familial Mediterranean FeverAnnals of Internal Medicine, 157
Nurdan Ibiş, S. Hocaoglu, M. Çebiçci, S. Sutbeyaz, H. Çalış (2015)
Palmoplantar pustular psoriasis induced by adalimumab: a case report and literature review.Immunotherapy, 7 7
Tessa Hanley, Zenas Yiu (2017)
Role of IL-17 in plaque psoriasis: therapeutic potential of ixekizumabTherapeutics and Clinical Risk Management, 13
Yuko Kawazoe, S. Sugita, Yukiko Yamada, Ai Akino, K. Miura, M. Mochizuki (2012)
Psoriasis triggered by infliximab in a patient with Behçet’s diseaseJapanese Journal of Ophthalmology, 57
A. Deisseroth, C. Ko, L. Nie, J. Zirkelbach, Liang Zhao, J. Bullock, N. Mehrotra, P. Valle, H. Saber, Christopher Sheth, Brenda Gehrke, R. Justice, A. Farrell, R. Pazdur (2015)
FDA Approval: Siltuximab for the Treatment of Patients with Multicentric Castleman DiseaseClinical Cancer Research, 21
L. Beck, D. Thaçi, J. Hamilton, N. Graham, T. Bieber, R. Rocklin, J. Ming, H. Ren, R. Kao, E. Simpson, M. Ardeleanu, S. Weinstein, G. Pirozzi, E. Guttman‐Yassky, M. Suárez-Fariñas, Melissa Hager, N. Stahl, G. Yancopoulos, A. Radin (2014)
Dupilumab treatment in adults with moderate-to-severe atopic dermatitis.The New England journal of medicine, 371 2
G. Keating (2015)
Mepolizumab: First Global ApprovalDrugs, 75
J. Oldhoff, U. Darsow, T. Werfel, K. Katzer, A. Wulf, J. Laifaoui, D. Hijnen, S. Plötz, E. Knol, A. Kapp, C. Bruijnzeel‐Koomen, Johannes Ring, M. Bruin-Weller (2005)
Anti‐IL‐5 recombinant humanized monoclonal antibody (Mepolizumab) for the treatment of atopic dermatitisAllergy, 60
C. Verros, E. Rallis, M. Crowe (2012)
Letter: Alopecia areata during ustekinumab administration: Co-existence or an adverse reaction?Dermatology online journal, 18 7
D. Khanna, C. Denton, A. Jahreis, J. Laar, T. Frech, Marina Anderson, M. Baron, L. Chung, G. Fierlbeck, S. Lakshminarayanan, Y. Allanore, J. Pope, G. Riemekasten, V. Steen, U. Müller-Ladner, R. Lafyatis, Giuseppina Stifano, H. Spotswood, Haiyin Chen-Harris, S. Dziadek, A. Morimoto, T. Sornasse, J. Siegel, D. Furst (2016)
Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trialThe Lancet, 387
A. Gül, H. Ozdogan, B. Erer, S. Uğurlu, O. Kasapcopur, N. Davis, S. Sevgi (2015)
Efficacy and safety of canakinumab in adolescents and adults with colchicine-resistant familial Mediterranean feverArthritis Research & Therapy, 17
J. Hoffmann, E. Hadaschik, A. Enk, W. Stremmel, A. Gauss (2015)
Linear IgA Bullous Dermatosis Secondary to Infliximab Therapy in a Patient with Ulcerative ColitisDermatology, 231
D. Nordström, A. Knight, R. Luukkainen, R. Vollenhoven, V. Rantalaiho, Anna Kajalainen, J. Brun, A. Prøven, L. Ljung, H. Kautiainen, T. Pettersson (2012)
Beneficial Effect of Interleukin 1 Inhibition with Anakinra in Adult-onset Still’s Disease. An Open, Randomized, Multicenter StudyThe Journal of Rheumatology, 39
M. Lacouture (2015)
Management of dermatologic toxicities.Journal of the National Comprehensive Cancer Network : JNCCN, 13 5 Suppl
W. Sandborn, B. Feagan, P. Rutgeerts, S. Hanauer, J. Colombel, B. Sands, M. Lukáš, R. Fedorak, S. Lee, B. Bressler, I. Fox, M. Rosario, S. Sankoh, Jing Xu, K. Stephens, C. Milch, A. Parikh (2013)
Vedolizumab as induction and maintenance therapy for Crohn's disease.The New England journal of medicine, 369 8
J. Lo, D. Fisher, K. Flaherty (2015)
Prognostic Significance of Cutaneous Adverse Events Associated With Pembrolizumab Therapy.JAMA oncology, 1 9
L. Khoja, L. Khoja, D. Day, D. Day, D. Day, T. Chen, L. Siu, L. Siu, A. Hansen, A. Hansen (2017)
Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic reviewAnnals of Oncology, 28
M. Lacouture, J. Wolchok, G. Yosipovitch, K. Kähler, K. Busam, A. Hauschild (2014)
Ipilimumab in patients with cancer and the management of dermatologic adverse events.Journal of the American Academy of Dermatology, 71 1
M. Fernández-Megía, B. Casanova, M. Magraner, I. Font-Noguera, J. Poveda-Andrés (2011)
Assessment of the effectiveness and safety of natalizumab for treating relapsing-remitting multiple sclerosis.Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria, 35 2
F. Vincenti, H. Silva, S. Busque, P. O’Connell, J. Friedewald, D. Cibrik, K. Budde, A. Yoshida, S. Cohney, W. Weimar, Y. Kim, N. Lawendy, S. Lan, E. Kudlacz, S. Krishnaswami, G. Chan (2012)
Randomized Phase 2b Trial of Tofacitinib (CP‐690,550) in De Novo Kidney Transplant Patients: Efficacy, Renal Function and Safety at 1 YearAmerican Journal of Transplantation, 12
A. Parikh, T. Leach, T. Wyant, C. Scholz, S. Sankoh, D. Mould, T. Ponich, I. Fox, B. Feagan (2012)
Vedolizumab for the Treatment of Active Ulcerative Colitis: A Randomized Controlled Phase 2 Dose‐ranging StudyInflammatory Bowel Diseases, 18
E. Conde-Montero, O. Baniandrés-Rodríguez, M. Mendoza-Cembranos, C. Horcajada-Reales, R. Suárez-Fernández (2014)
Psoriasiform reactions during treatment with abatacept.Indian journal of dermatology, venereology and leprology, 80 1
P. Boura, A. Sarantopoulos, I. Lefaki, P. Skendros, P. Papadopoulos (2006)
Eosinophilic cellulitis (Wells’ syndrome) as a cutaneous reaction to the administration of adalimumabAnnals of the Rheumatic Diseases, 65
Emily Stamell, A. Kutner, K. Viola, Steven Cohen (2013)
Ustekinumab associated with flares of psoriatic arthritis.JAMA dermatology, 149 12
P. Mease, M. Genovese, G. Gladstein, A. Kivitz, C. Ritchlin, P. Tak, J. Wollenhaupt, O. Bahary, J. Becker, S. Kelly, L. Sigal, J. Teng, D. Gladman (2011)
Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial.Arthritis and rheumatism, 63 4
Tiana Kazemi, B. Farahnik, J. Koo, Kourosh Beroukhim (2017)
Emerging targeted therapies for plaque psoriasis – impact of ixekizumabClinical, Cosmetic and Investigational Dermatology, 10
W. Stohl, A. Schwarting, M. Okada, M. Scheinberg, A. Doria, A. Hammer, C. Kleoudis, J. Groark, D. Bass, N. Fox, D. Roth, D. Gordon (2017)
Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty‐Two–Week Randomized, Double‐Blind, Placebo‐Controlled StudyArthritis & Rheumatology (Hoboken, N.j.), 69
L. Iaccarino, L. Andreoli, E. Bocci, A. Bortoluzzi, F. Ceccarelli, F. Conti, R. Angelis, G. Marchi, S. Vita, A. Matteo, G. Emmi, L. Emmi, M. Gatto, R. Gerli, M. Gerosa, M. Govoni, M. Larosa, P. Meroni, M. Mosca, G. Pazzola, R. Reggia, F. Saccon, C. Salvarani, C. Tani, M. Zen, A. Frigo, A. Tincani, A. Doria (2018)
Clinical predictors of response and discontinuation of belimumab in patients with systemic lupus erythematosus in real life setting. Results of a large, multicentric, nationwide study.Journal of autoimmunity, 86
Hannah Blair, E. Deeks (2017)
Abatacept: A Review in Rheumatoid ArthritisDrugs, 77
H. Teulings, J. Limpens, Sophia Jansen, A. Zwinderman, J. Reitsma, P. Spuls, R. Luiten (2015)
Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 33 7
G. Mocci, M. Marzo, A. Papa, A. Armuzzi, L. Guidi (2013)
Dermatological adverse reactions during anti-TNF treatments: focus on inflammatory bowel disease.Journal of Crohn's & colitis, 7 10
C. Robert, J. Schachter, G. Long, A. Arance, J. Grob, L. Mortier, A. Daud, M. Carlino, C. McNeil, M. Lotem, J. Larkin, P. Lorigan, B. Neyns, C. Blank, O. Hamid, C. Mateus, R. Shapira-Frommer, M. Kosh, Honghong Zhou, N. Ibrahim, S. Ebbinghaus, A. Ribas (2015)
Pembrolizumab versus Ipilimumab in Advanced Melanoma.The New England journal of medicine, 372 26
Faping Wang, Ting Liu, Zhu Lan, Suyun Li, Hui Mao (2016)
Efficacy and Safety of Anti-Interleukin-5 Therapy in Patients with Asthma: A Systematic Review and Meta-AnalysisPLoS ONE, 11
V. Failla, Jessica Jacques, C. Castronovo, A. Nikkels (2012)
Herpes Zoster in Patients Treated with BiologicalsDermatology, 224
J. Salzer, Rasmus Svenningsson, Peter Alping, L. Novakova, Anna Björck, K. Fink, Protik Islam-Jakobsson, C. Malmeström, M. Axelsson, Mattias Vågberg, P. Sundström, J. Lycke, F. Piehl, A. Svenningsson (2016)
Rituximab in multiple sclerosisNeurology, 87
M. Rothenberg, A. Klion, F. Roufosse, J. Kahn, P. Weller, H. Simon, L. Schwartz, L. Rosenwasser, J. Ring, E. Griffin, A. Haig, P. Frewer, J. Parkin, G. Gleich (2008)
Treatment of patients with the hypereosinophilic syndrome with mepolizumab.The New England journal of medicine, 358 12
C. Pernet, B. Guillot, D. Bessis (2012)
Eczematous drug eruption after ustekinumab treatment.Archives of dermatology, 148 8
J. Kelsall, P. Rogers, G. Galindo, M. Vera (2012)
Safety of Infliximab Treatment in Patients with Rheumatoid Arthritis in a Real-world Clinical Setting: Description and Evaluation of Infusion ReactionsThe Journal of Rheumatology, 39
M. Akiyama (2017)
Trial of Tocilizumab in Giant-Cell Arteritis.The New England journal of medicine, 377 15
T. Kullenberg, M. Löfqvist, M. Leinonen, R. Goldbach-Mansky, H. Olivecrona (2016)
Long-term safety profile of anakinra in patients with severe cryopyrin-associated periodic syndromesRheumatology (Oxford, England), 55
J. Sundy, H. Schumacher, A. Kivitz, S. Weinstein, R. Wu, Shirletta King-Davis, R. Evans (2014)
Rilonacept for Gout Flare Prevention in Patients Receiving Uric Acid-lowering Therapy: Results of RESURGE, a Phase III, International Safety StudyThe Journal of Rheumatology, 41
B. Sands, R. Kozarek, J. Spainhour, C. Barish, S. Becker, L. Goldberg, S. Katz, R. Goldblum, R. Harrigan, D. Hilton, S. Hanauer (2007)
Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximabInflammatory Bowel Diseases, 13
V. Rocchi, I. Puxeddu, G. Cataldo, I. Corso, A. Tavoni, L. Bazzichi, S. Bombardieri, P. Migliorini (2014)
Hypersensitivity reactions to tocilizumab: role of skin tests in diagnosis.Rheumatology, 53 8
J. Weber, K. Kähler, A. Hauschild (2012)
Management of immune-related adverse events and kinetics of response with ipilimumab.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 21
Purpose of Review The goal of this paper is to review the major adverse cutaneous reactions that have been reported to the most commonly used biologics. Recent Findings Anti-TNF agents and immune checkpoint inhibitors have significant, immune-mediated cutaneous manifestations that can necessitate discontinuation. Anti-TNF agents, IL-6 inhibitors, and IL-12/23 inhibitors can paradoxically cause psoriasis flares or unmask previously undiagnosed psoriasis. IL-17 inhibitors are unique in increasing risk for Candida infections. Benign injection site reactions, non-specific rash, cellulitis, and hypersensi- tivity reactions are relatively common adverse events. Summary A wide variety of cutaneous reactions caused by biologics have been reported, ranging from benign injection site reactions to life-threatening cutaneous reactions necessitating discontinuation of the implicated biologic agent. . . . . . Keywords Cutaneous reactions Biologics Biological therapies Anti-TNF agents IL-6 inhibitors IL-12/23 inhibitors Abbreviations IL-6 inhibitors TNF Tumor necrosis factor B-cell depletion IBD Inflammatory bowel disease IL-12/23 inhibitors ISRs Injection site reactions IL-17 inhibitors CAPS Cryopyrin-associated periodic syndromes Immune checkpoint inhibitors FMF Familial Mediterranean fever IL-4/13 inhibitors TRAPS TNF receptor-1-associated periodic syndrome IL-5 inhibitors HSRs Hypersensitivity reactions JAK3 inhibitor SLE Systemic lupus erythematosus Costimulation blockade irAEs Immune-related adverse effects Integrin receptor antagonists Summary Introduction TNF-α inhibitors Biological therapies are
Current Allergy and Asthma Reports – Springer Journals
Published: Feb 21, 2018
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.